This article reviews the initial experience with chemotherapy in metastatic castration-resistant prostate cancer (mCRPC) and outlines some of the ongoing clinical trials in this area.
In addition, the authors outline current knowledge on outcomes of patients treated with taxane-based chemotherapy on retrospective analysis of randomized trials. These data are intended to provide physicians and patients with a general idea on the outcomes of men with mCRPC that may facilitate clinical decisions as well as the design and evaluation of clinical trials.
Written by:
Eisenberger MA, Antonarakis ES. Are you the author?
Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University, Baltimore, MD, USA.
Reference: Urol Clin North Am. 2012 Nov;39(4):573-81.
doi: 10.1016/j.ucl.2012.07.012
PubMed Abstract
PMID: 23084532
UroToday.com Prostate Cancer Section
